Published in J Infect Dis on May 01, 1991
Induction of AIDS by simian immunodeficiency virus from an African green monkey: species-specific variation in pathogenicity correlates with the extent of in vivo replication. J Virol (1995) 2.96
A molecularly cloned, pathogenic, neutralization-resistant simian immunodeficiency virus, SIVsmE543-3. J Virol (1997) 2.46
Viral sanctuaries during highly active antiretroviral therapy in a nonhuman primate model for AIDS. J Virol (2009) 2.37
Simian immunodeficiency virus replicates to high levels in naturally infected African green monkeys without inducing immunologic or neurologic disease. J Virol (2001) 2.29
Development of AIDS in a chimpanzee infected with human immunodeficiency virus type 1. J Virol (1997) 1.66
Eradicating HIV-1 infection: seeking to clear a persistent pathogen. Nat Rev Microbiol (2014) 1.65
Unique pathology in simian immunodeficiency virus-infected rapid progressor macaques is consistent with a pathogenesis distinct from that of classical AIDS. J Virol (2007) 1.44
Spontaneous substitutions in the vicinity of the V3 analog affect cell tropism and pathogenicity of simian immunodeficiency virus. J Virol (1994) 1.39
Novel adeno-associated virus vector vaccine restricts replication of simian immunodeficiency virus in macaques. J Virol (2005) 1.36
Inactivated whole-virus vaccine derived from a proviral DNA clone of simian immunodeficiency virus induces high levels of neutralizing antibodies and confers protection against heterologous challenge. Proc Natl Acad Sci U S A (1992) 1.35
Monocyte maturation controls expression of equine infectious anemia virus. J Virol (1994) 1.29
Loss of naïve cells accompanies memory CD4+ T-cell depletion during long-term progression to AIDS in Simian immunodeficiency virus-infected macaques. J Virol (2006) 1.27
Immune failure in the absence of profound CD4+ T-lymphocyte depletion in simian immunodeficiency virus-infected rapid progressor macaques. J Virol (2004) 1.25
Heterogeneity in neutralization sensitivities of viruses comprising the simian immunodeficiency virus SIVsmE660 isolate and vaccine challenge stock. J Virol (2013) 1.18
Extensive envelope heterogeneity of simian immunodeficiency virus in tissues from infected macaques. J Virol (1994) 1.09
The simian immunodeficiency virus envelope glycoprotein contains two epitopes presented by the Mamu-A*01 class I molecule. J Virol (1999) 1.04
Improbability of effective vaccination against human immunodeficiency virus because of its intracellular transmission and rectal portal of entry. Proc Natl Acad Sci U S A (1992) 1.04
A rapid progressor-specific variant clone of simian immunodeficiency virus replicates efficiently in vivo only in the absence of immune responses. J Virol (2007) 0.89
Restricted SIV replication in rhesus macaque lung tissues during the acute phase of infection. Am J Pathol (2002) 0.88
Chronic alcohol abuse and HIV disease progression: studies with the non-human primate model. Curr HIV Res (2014) 0.84
Selective expression of human immunodeficiency virus Nef in specific immune cell populations of transgenic mice is associated with distinct AIDS-like phenotypes. J Virol (2009) 0.80
Comparison of the effects of 3'-azidothymidine with those of neutralizing antibodies on simian immunodeficiency virus infection in macrophages. Antimicrob Agents Chemother (1993) 0.75
An African primate lentivirus (SIVsm) closely related to HIV-2. Nature (1989) 5.03
The G glycoprotein of human respiratory syncytial viruses of subgroups A and B: extensive sequence divergence between antigenically related proteins. Proc Natl Acad Sci U S A (1987) 4.93
Expression of the F glycoprotein of respiratory syncytial virus by a recombinant vaccinia virus: comparison of the individual contributions of the F and G glycoproteins to host immunity. Proc Natl Acad Sci U S A (1986) 4.14
SIV adaptation to human cells. Nature (1989) 3.09
Induction of AIDS by simian immunodeficiency virus from an African green monkey: species-specific variation in pathogenicity correlates with the extent of in vivo replication. J Virol (1995) 2.96
Plasma viremia in macaques infected with simian immunodeficiency virus: plasma viral load early in infection predicts survival. J Virol (1997) 2.81
Highly purified recombinant adeno-associated virus vectors are biologically active and free of detectable helper and wild-type viruses. Hum Gene Ther (1999) 2.73
Species-specific diversity among simian immunodeficiency viruses from African green monkeys. J Virol (1991) 2.70
Titration and characterization of two rhesus-derived SIVmac challenge stocks. AIDS Res Hum Retroviruses (1994) 2.63
Diet-induced adipocyte number increase in adult rats: a new model of obesity. Am J Physiol (1978) 2.62
Loss of functional KATP channels in pancreatic beta-cells causes persistent hyperinsulinemic hypoglycemia of infancy. Nat Med (1996) 2.40
Pathogenic diversity of simian immunodeficiency viruses. Virus Res (1994) 2.27
Antigenic relatedness between glycoproteins of human respiratory syncytial virus subgroups A and B: evaluation of the contributions of F and G glycoproteins to immunity. J Virol (1987) 2.26
Nucleotide sequence analysis of feline immunodeficiency virus: genome organization and relationship to other lentiviruses. Proc Natl Acad Sci U S A (1989) 2.21
Vaccination of macaques against pathogenic simian immunodeficiency virus with Venezuelan equine encephalitis virus replicon particles. J Virol (2000) 2.09
TENTATIVE CLASSIFICATION OF SYMPTOMATIC TYPES OF "TOMATO POCKETS". Plant Physiol (1930) 2.00
Immunity to influenza A virus infection in young children: a comparison of natural infection, live cold-adapted vaccine, and inactivated vaccine. J Infect Dis (1986) 1.97
Recombinant adeno-associated viral vectors mediate long-term transgene expression in muscle. Hum Gene Ther (1997) 1.93
Molecular cloning of feline immunodeficiency virus. Proc Natl Acad Sci U S A (1989) 1.92
Comparison of long-term systemic and secretory antibody responses in children given live, attenuated, or inactivated influenza A vaccine. J Med Virol (1985) 1.88
Passive immune globulin therapy in the SIV/macaque model: early intervention can alter disease profile. Immunol Lett (1996) 1.87
Cellularity of adipose depots in six strains of genetically obese mice. J Lipid Res (1972) 1.84
Antigen presentation requires transport of MHC class I molecules from the endoplasmic reticulum. Science (1990) 1.79
Association of Ebola-related Reston virus particles and antigen with tissue lesions of monkeys imported to the United States. J Comp Pathol (1992) 1.78
Changing nature of physician satisfaction with health maintenance organization and fee-for-service practices. J Fam Pract (1997) 1.72
The two open reading frames of the 22K mRNA of human respiratory syncytial virus: sequence comparison of antigenic subgroups A and B and expression in vitro. J Gen Virol (1990) 1.71
Gene overlap and site-specific attenuation of transcription of the viral polymerase L gene of human respiratory syncytial virus. Proc Natl Acad Sci U S A (1987) 1.69
SUMO-1: Ubiquitin gains weight. Trends Cell Biol (1997) 1.68
Adeno-associated virus-mediated gene transfer to the brain: duration and modulation of expression. Hum Gene Ther (1999) 1.67
Cell lines for the production of recombinant adeno-associated virus. Hum Gene Ther (1995) 1.62
A highly divergent proviral DNA clone of SIV from a distinct species of African green monkey. Virology (1991) 1.61
A distinct African lentivirus from Sykes' monkeys. J Virol (1993) 1.58
Selective infection of human CD4+ cells by simian immunodeficiency virus: productive infection associated with envelope glycoprotein-induced fusion. Proc Natl Acad Sci U S A (1989) 1.56
Familial persistent hyperinsulinemic hypoglycemia of infancy and mutations in the sulfonylurea receptor. N Engl J Med (1997) 1.55
Sensitization alters contractile responses and calcium influx in human airway smooth muscle. J Allergy Clin Immunol (1989) 1.55
Dual-target inhibition of HIV-1 in vitro by means of an adeno-associated virus antisense vector. Science (1992) 1.54
Relationship of plasma leptin to plasma insulin and adiposity in normal weight and overweight women: effects of dietary fat content and sustained weight loss. J Clin Endocrinol Metab (1996) 1.53
A stable cell line carrying adenovirus-inducible rep and cap genes allows for infectivity titration of adeno-associated virus vectors. Gene Ther (1996) 1.52
Identification of a new subgroup of SIVagm in tantalus monkeys. Virology (1993) 1.50
Multiple viral determinants contribute to pathogenicity of the acutely lethal simian immunodeficiency virus SIVsmmPBj variant. J Virol (1993) 1.49
Somatostatin release, electrical activity, membrane currents and exocytosis in human pancreatic delta cells. Diabetologia (2009) 1.46
Entangled macroscopic quantum States in two superconducting qubits. Science (2003) 1.41
Mitozantrone and cytosine arabinoside as first-line therapy in elderly patients with acute myeloid leukaemia. Br J Haematol (1991) 1.40
Spontaneous substitutions in the vicinity of the V3 analog affect cell tropism and pathogenicity of simian immunodeficiency virus. J Virol (1994) 1.39
Rhabdomyosarcoma presenting as 'acute leukaemia'. Histopathology (1991) 1.38
Combined simian hemorrhagic fever and Ebola virus infection in cynomolgus monkeys. Lab Anim Sci (1992) 1.36
The small hydrophobic protein of human respiratory syncytial virus: comparison between antigenic subgroups A and B. J Gen Virol (1990) 1.32
Effects of innate immunity on herpes simplex virus and its ability to kill tumor cells. Gene Ther (2003) 1.31
The action of a potassium channel activator, BRL 38227 (lemakalim), on human airway smooth muscle. Am Rev Respir Dis (1990) 1.30
SIV from stump-tailed macaques: molecular characterization of a highly transmissible primate lentivirus. Virology (1992) 1.29
Complement control proteins, CD46, CD55, and CD59, as common surface constituents of human and simian immunodeficiency viruses and possible targets for vaccine protection. Virology (1994) 1.25
Unique lentivirus--host interactions: SIVsmmPBj14 infection of macaques. Virus Res (1994) 1.22
Cellularity of adipose depots in the genetically obese Zucker rat. J Lipid Res (1971) 1.22
Antibody-dependent enhancement of simian immunodeficiency virus (SIV) infection in vitro by plasma from SIV-infected rhesus macaques. J Virol (1990) 1.20
Clinicopathologic findings associated with chronic renal disease in cats: 74 cases (1973-1984). J Am Vet Med Assoc (1987) 1.19
Using the polymerase chain reaction to genotype human papillomavirus DNAs in samples containing multiple HPVs may produce inaccurate results. J Virol Methods (1993) 1.18
Pharmacokinetics and safety of an anti-vascular endothelial growth factor aptamer (NX1838) following injection into the vitreous humor of rhesus monkeys. Pharm Res (2000) 1.14
Ionic control of beta cell function in nesidioblastosis. A possible therapeutic role for calcium channel blockade. Arch Dis Child (1996) 1.14
Prolonged clinical latency and survival of macaques given a whole inactivated simian immunodeficiency virus vaccine. J Infect Dis (1994) 1.13
Comparative efficacies of liposomal amikacin (MiKasome) plus oxacillin versus conventional amikacin plus oxacillin in experimental endocarditis induced by Staphylococcus aureus: microbiological and echocardiographic analyses. Antimicrob Agents Chemother (1999) 1.12
Selective Rep-Cap gene amplification as a mechanism for high-titer recombinant AAV production from stable cell lines. Mol Ther (2000) 1.12
Brief periods of hyperphagia cause renal injury in the obese Zucker rat. Kidney Int (1999) 1.08
Summary report: workshop on the potential risks of antibody-dependent enhancement in human HIV vaccine trials. AIDS Res Hum Retroviruses (1993) 1.05
A fatal cytokine-induced systemic inflammatory response reveals a critical role for NK cells. J Immunol (1999) 1.05
The Saccharomyces cerevisiae ubiquitin-proteasome system. Philos Trans R Soc Lond B Biol Sci (1999) 1.04
A longitudinal study of body fatness in childhood and adolescence. J Pediatr (1979) 1.04
The simian immunodeficiency virus envelope glycoprotein contains two epitopes presented by the Mamu-A*01 class I molecule. J Virol (1999) 1.04
Infection of rhesus and cynomolgus macaques with a rapidly fatal SIV (SIVSMM/PBj) isolate from sooty mangabeys. AIDS Res Hum Retroviruses (1992) 1.03
Molecular cloning of SIV from sooty mangabey monkeys. J Med Primatol (1989) 1.02
Animal models for acquired immunodeficiency syndrome. Adv Immunol (1992) 1.02
Spontaneous activity and adipose cellularity in the genetically obese Zucker rat (fafa). Metabolism (1977) 1.02
Characterization of contractile prostanoid receptors on human airway smooth muscle. Eur J Pharmacol (1989) 1.01
Immunological and virological changes associated with decline in CD4/CD8 ratios in lymphoid organs of SIV-infected macaques. AIDS Res Hum Retroviruses (1994) 1.01
Gene transfer into the CNS using recombinant adeno-associated virus: analysis of vector DNA forms resulting in sustained expression. J Drug Target (1999) 1.00
ERK activation and mitogenesis in human airway smooth muscle cells. Am J Physiol Lung Cell Mol Physiol (2001) 1.00
Gene delivery of vaccines for infectious disease. Curr Opin Mol Ther (2001) 0.98
Correlation of NADH and Ca2+ signals in mouse pancreatic acinar cells. J Physiol (2002) 0.97
Interleukin-4 inhibits mitogen-induced proliferation of human airway smooth muscle cells in culture. Am J Physiol (1998) 0.97
Insulin resistance and pancreatic insulin release in the genetically obese Zucker rat. Proc Soc Exp Biol Med (1972) 0.97
Human pancreatic islet isolation and transplantation. Clin Transplant (1994) 0.97
Adipose tissue regeneration following lipectomy. Science (1977) 0.96
Potentiation of the contractile effects of neuropeptides in human bronchus by an enkephalinase inhibitor. Pulm Pharmacol (1988) 0.96
Health care utilisation following hospitalisation for transport-related injury. Injury (2011) 0.96
Production of recombinant adeno-associated virus vectors using a packaging cell line and a hybrid recombinant adenovirus. Gene Ther (1999) 0.96
Surgical removal of adipose tissue alters feeding behavior and the development of obesity in rats. Science (1977) 0.95
The chemistry of site-directed serology for HIV infections. AIDS Res Hum Retroviruses (1989) 0.95
Therapy for persistent hyperinsulinemic hypoglycemia of infancy. Understanding the responsiveness of beta cells to diazoxide and somatostatin. J Clin Invest (1997) 0.95
Regulatory decision strategy for entry of a novel biological therapeutic with a clinically unmonitorable toxicity into clinical trials: pre-IND meetings and a case example. Toxicol Pathol (1999) 0.94
Molecular diversity of SIVsmm/PBj and a cognate variant, SIVsmm/PGg. J Med Primatol (1991) 0.94
Factors predicting outcome after selective ERCP in the laparoscopic era. Ann R Coll Surg Engl (1995) 0.94
Recombinant adeno-associated virus-mediated correction of lysosomal storage within the central nervous system of the adult mucopolysaccharidosis type VII mouse. Hum Gene Ther (2000) 0.93
In vivo MRI characteristics of lipoma arborescens utilizing fat suppression and contrast administration. J Comput Assist Tomogr (1996) 0.93
Decline in the CD4+ lymphocyte population in the blood of SIV-infected macaques is not reflected in lymph nodes. AIDS Res Hum Retroviruses (1993) 0.92
Tumour necrosis factor-alpha potentiates contraction of human bronchus in vitro. Respirology (2001) 0.92
An evaluation of the toxicities of 2'-fluorouridine and 2'-fluorocytidine-HCl in F344 rats and woodchucks (Marmota monax). Toxicol Pathol (2000) 0.92
Infection of Macaca radiata with viruses of the tick-borne encephalitis group. Microb Pathog (1992) 0.92
Frequency of broviac catheter infections in pediatric oncology patients. J Infect Dis (1986) 0.92
Effect of early nutrition on adipose cellularity and pancreatic insulin release in the Zucker rat. J Nutr (1973) 0.91
Viral genetic determinants in SIVsmmPBj pathogenesis. J Med Primatol (1994) 0.91